A Phase 4 interventional study of SAR231893 and Placebo in Asthma, sponsored by Sanofi. Completed at 55 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-06.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.
Among the 31 studies testing dupilumab in Asthma, this one is the 13th largest by enrollment, is one of 4 that started in 2020, is one of 14 in phase 4, and was the 18th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
Université de Sherbrooke · Sites in Australia, Canada, United Kingdom
Ages 18–79
University Hospital, Toulouse · Sites in France
Ages 18+
University of California, San Diego · Sites in United States
Ages 18–75
Sally E. Wenzel MD · Sites in United States
Ages 18+
University of Virginia · Sites in United States
Ages 18–40
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
31 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2020.
This study's enrollment of 202 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 120 across the 31 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
37 studies in Asthma by Sanofi: 3 open now, 5 under way, 1 of them phase 3. Of 32 finished, 14 (44%) have results posted.
Among the 37 studies in Asthma by Sanofi, this one is the 25th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 4, and was the 22nd registered.
Sanofi’s Asthma studies by the year they started, since 2000.
5 of the studies testing dupilumab in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347771National Institute of Allergy and Infectious Diseases (NIAID)Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents | 2026-12-31 |
| NCT03694158Boston Children's HospitalInvestigating Dupilumab's Effect in Asthma by Genotype | 2027-01 |
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06572228Regeneron PharmaceuticalsEfficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | 2027-04-24 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies testing dupilumab in Asthma, from their registry updates:
Among Sanofi’s 37 in Asthma:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To assess the effect of dupilumab on sleep
Secondary Objectives:
Study duration per participant was approximately 16 weeks and up to 29 weeks including up to 5 weeks screening period, a 12-week treatment period and up to 12 weeks post-treatment follow-up period or until the participant switched to commercialized dupilumab (or other biologic product), whichever came first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eosinophils ≥150 cells/μL and fractional exhaled nitric oxide (FeNO) ≥25 ppb during screening, prior to randomization
Exclusion Criteria:
Treatment with live (attenuated) vaccine within 4 weeks before screening Visit 1
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a loading dose of 400 mg of dupilumab (2 injections × 200 mg) SC on Day 1, followed by 200 mg Q2W for 12 weeks.
Drug: SAR231893
Participants received an initial loading dose of matching placebo (2 injections of placebo) SC on Day 1, followed by 1 injection of placebo Q2W for 12 weeks.
Drug: Placebo
Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Also known as: Dupixent
Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Change From Baseline to Week 12 in Sleep Disturbance Score Using the Asthma Sleep Disturbance Questionnaire (ASDQ)
The ASDQ is a participant-reported outcome (PRO) measure designed to assess the impact of asthma on participants' sleep. Participants were instructed to record the severity of the disturbance of their sleep due to asthma as: 0 = slept through the night, no asthma symptoms; 1 = slept well, no night time awakenings because of asthma, but some asthma symptoms in the morning; 2 = woke up once because of asthma (may or may not include early awakening); 3 = woke up several times because of asthma (may or may not include early awakening) and 4 = bad night, awake most of the night because of asthma. The participants recorded their sleep disturbance in an electronic diary, once a day upon awakening. Total scores ranges between 0 to 4 with 0 indicating no impact of asthma on sleep and 4 indicating higher impact of asthma on sleep. Higher scores indicated worse outcomes. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.
Time frame: Baseline (Day -6 to Day 1) up to Week 12
Change From Baseline to Week 12 on the Number of Nocturnal Awakenings (Sleep Diary)
Sleep diary is used to assess adult sleep disturbance due to asthma. Number of nocturnal awakenings was determined based on answer on question from sleep diary: "Approximately how many times did you wake up last night (not including when you woke up for the day today)?" Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.
Time frame: Baseline (Day -6 to Day 1) up to Week 12
Change From Baseline to Week 12 in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment 8a Scale
PROMIS sleep-related impairment eight-term 8a scale was administered to assess impact of sleep-related impairment during waking hours. The questionnaire focuses on self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. It assesses sleep-related impairment over the past 7 days. Each item is rated on a 5-point scale (1 = not at all; 2 = a little bit; 3 = somewhat; 4 = quite a bit; and 5 = very much) with a raw score from 8 to 40 with higher scores indicating greater sleep impairment. PROMIS T-score is presented which rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. Possible range for T-score=30 to 80; higher scores=greater severity of sleep impairment. Baseline=last available valid (non-missing) value up to and including the day of first dose of investigational medicinal product (IMP).
Time frame: Baseline (Day 1) up to Week 12
Change From Baseline to Week 12 in Sleep Quality (Sleep Diary)
Sleep diary is used to assess adult sleep disturbance due to asthma. Sleep quality was assessed on a 11-point scale which ranged from 0 (worst possible sleep) to 10 (best possible sleep); higher scores indicated better outcomes. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.
Time frame: Baseline (Day -6 to Day 1) up to Week 12
Change From Baseline to Week 12 in Restorative Sleep (Sleep Diary)
Sleep Diary is used to assess adult sleep disturbance due to asthma. Question about restorative sleep asks participants to recall "when they got up for the day today". Restorative sleep was assessed on a 11-point scale which ranged from 0 (worst possible sleep) to 10 (best possible sleep); higher scores indicated better outcomes. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.
Time frame: Baseline (Day -6 to Day 1) up to Week 12
Change From Baseline to Week 12 in Wake After Sleep Onset (WASO) (Sleep Diary)
Sleep Diary is used to assess adult sleep disturbance due to asthma. WASO was calculated as time awake after initial sleep onset but before the final awakening. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.
Time frame: Baseline (Day -6 to Day 1) up to Week 12
Change From Baseline to Week 12 in WASO Based on Actigraphy Data
Wrist actigraphy is a procedure that records and integrates occurrence and degree of limb movement activity over an extended recording period. The signals generated by wrist movement are sensed by a tiny microcomputer contained within watch and translated into activity counts. Algorithms have been developed to translate these activity counts or "epochs" (or "periods") that correspond to times when a person is likely to be asleep or wake. Actigraph was worn on wrist of non-dominant hand to provide estimates of duration, timing and patterns of sleep in study participants. After the watch data were scored by a selected expert center, a number of summary measurements were generated for each participant, including WASO. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.
Time frame: Baseline (Day -6 to Day 1) up to Week 12
Change From Baseline to Week 12 in Asthma Daytime Symptom Diary (ADSD)
The ADSD is a PRO measure designed to measure asthma symptoms in adult and adolescent (12 years of age and older) participants diagnosed with mild to severe asthma. ADSD assesses asthma severity based on participant self-report of asthma core symptoms, i.e., difficulty breathing, wheezing, shortness of breath, chest tightness, chest pain, and cough. Participants were asked to complete the ADSD every night before they go to bed, thinking about their asthma symptoms today, from when they got up this morning until now. ADSD is composed of 6 items rated using an 11-point NRS that ranges from 0 = None to 10 = as bad as you can imagine. The total score was calculated by averaging all 6 items and therefore the score ranged from 0 to 10. Higher scores indicated worse outcomes. Baseline value was average of the data from Day -7 to Day -1.
Time frame: Baseline (Day -7 to Day -1) up to Week 12
Change From Baseline to Week 12 in Asthma Nighttime Symptom Diary (ANSD)
The ANSD is a PRO measure designed to measure asthma symptoms in adult and adolescent (12 years of age and older) participants diagnosed with mild to severe asthma. ANSD assesses asthma severity based on participant self-report of asthma core symptoms, i.e., difficulty breathing, wheezing, shortness of breath, chest tightness, chest pain, and cough. Participants were asked to complete the ANSD when getting up, thinking about their asthma symptoms last night from when they went to bed until now. ANSD is composed of 6 items rated using an 11-point NRS that ranges from 0 = None to 10 = as bad as you can imagine. The total score was calculated by averaging all 6 items and therefore the score ranged from 0 to 10. Higher scores indicated worse outcomes. Baseline value was average of the data from Day -6 to Day -1.
Time frame: Baseline (Day -6 to Day -1) up to Week 12
Change From Baseline to Week 12 in Pre-Bronchodilator Forced Expiratory Volume (Pre-BD FEV1)
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. For pre-BD FEV1, spirometry was performed before IMP administration and after withholding the standard of care asthma treatment which was verified before performing the measurements. Baseline was defined as the last available valid (non-missing) value up to and including the day of first dose of IMP.
Time frame: Baseline (Day 1) up to Week 12
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Treatment-Emergent Adverse Events Of Special Interest (TEAESIs)
AE: any untoward medical occurrence in participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs: AEs that developed or worsened or became serious during TEAE period, defined as time from first administration of IMP (on Day 1) to last administration of IMP + 98 days or until participant switches to commercialized dupilumab or other biologics. SAE: any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. AESI: AE (serious or nonserious) of scientific and medical concern specific to Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor is required.
Time frame: From first dose of study drug (Day 1) up to 12 weeks after last dose of study drug, approximately 30 weeks
Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Vital Signs
Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR) and weight. Criteria for PCSA: SBP: ≤95 millimeters of mercury (mmHg) and decrease from baseline ≥20 mmHg, ≥160 mmHg and increase from baseline ≥20 mmHg; DBP: ≤45 mmHg and decrease from baseline ≥10 mmHg, ≥ 110 mmHg and increase from baseline ≥ 10 mmHg; HR: ≤ 50 beats per minute (bpm) and decrease from baseline ≥ 20 bpm, ≥120 bpm and increase from baseline ≥ 20 bpm; Weight: ≥ 5% increase from baseline, ≥5% decrease from baseline.
Time frame: From first dose of study drug (Day 1) up to 12 weeks after last dose of study drug, approximately 30 weeks
The study was conducted at 52 centers in 11 countries. A total of 397 participants were screened between 10 August 2020 to 30 May 2023, of which 195 participants were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.
| Milestone | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| Started | 101 | 101 |
| Randomized and treated | 100 | 101 |
| Completed | 95 | 94 |
| Not completed | 6 | 7 |
| Withdrew: Not related to coronavirus disease-2019 (covid-19) pandemic | 4 | 6 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 |
The ASDQ is a participant-reported outcome (PRO) measure designed to assess the impact of asthma on participants' sleep. Participants were instructed to record the severity of the disturbance of their sleep due to asthma as: 0 = slept through the night, no asthma symptoms; 1 = slept well, no night time awakenings because of asthma, but some asthma symptoms in the morning; 2 = woke up once because of asthma (may or may not include early awakening); 3 = woke up several times because of asthma (may or may not include early awakening) and 4 = bad night, awake most of the night because of asthma. The participants recorded their sleep disturbance in an electronic diary, once a day upon awakening. Total scores ranges between 0 to 4 with 0 indicating no impact of asthma on sleep and 4 indicating higher impact of asthma on sleep. Higher scores indicated worse outcomes. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.
| Score on a scale | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in Sleep Disturbance Score Using the Asthma Sleep Disturbance Questionnaire (ASDQ) | -0.88 ± 0.077 | -0.81 ± 0.077 |
Sleep diary is used to assess adult sleep disturbance due to asthma. Number of nocturnal awakenings was determined based on answer on question from sleep diary: "Approximately how many times did you wake up last night (not including when you woke up for the day today)?" Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.
| Number of nocturnal awakenings | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| Change From Baseline to Week 12 on the Number of Nocturnal Awakenings (Sleep Diary) | -0.71 ± 0.080 | -0.71 ± 0.080 |
PROMIS sleep-related impairment eight-term 8a scale was administered to assess impact of sleep-related impairment during waking hours. The questionnaire focuses on self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. It assesses sleep-related impairment over the past 7 days. Each item is rated on a 5-point scale (1 = not at all; 2 = a little bit; 3 = somewhat; 4 = quite a bit; and 5 = very much) with a raw score from 8 to 40 with higher scores indicating greater sleep impairment. PROMIS T-score is presented which rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. Possible range for T-score=30 to 80; higher scores=greater severity of sleep impairment. Baseline=last available valid (non-missing) value up to and including the day of first dose of investigational medicinal product (IMP).
| T-score | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment 8a Scale | -7.20 ± 0.624 | -6.51 ± 0.626 |
Sleep diary is used to assess adult sleep disturbance due to asthma. Sleep quality was assessed on a 11-point scale which ranged from 0 (worst possible sleep) to 10 (best possible sleep); higher scores indicated better outcomes. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.
| Score on a scale | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in Sleep Quality (Sleep Diary) | 1.14 ± 0.151 | 0.97 ± 0.152 |
Sleep Diary is used to assess adult sleep disturbance due to asthma. Question about restorative sleep asks participants to recall "when they got up for the day today". Restorative sleep was assessed on a 11-point scale which ranged from 0 (worst possible sleep) to 10 (best possible sleep); higher scores indicated better outcomes. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.
| Score on a scale | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in Restorative Sleep (Sleep Diary) | 1.15 ± 0.152 | 1.02 ± 0.152 |
Sleep Diary is used to assess adult sleep disturbance due to asthma. WASO was calculated as time awake after initial sleep onset but before the final awakening. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.
| Minutes | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in Wake After Sleep Onset (WASO) (Sleep Diary) | -30.58 ± 3.945 | -26.48 ± 3.962 |
Wrist actigraphy is a procedure that records and integrates occurrence and degree of limb movement activity over an extended recording period. The signals generated by wrist movement are sensed by a tiny microcomputer contained within watch and translated into activity counts. Algorithms have been developed to translate these activity counts or "epochs" (or "periods") that correspond to times when a person is likely to be asleep or wake. Actigraph was worn on wrist of non-dominant hand to provide estimates of duration, timing and patterns of sleep in study participants. After the watch data were scored by a selected expert center, a number of summary measurements were generated for each participant, including WASO. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.
| Minutes | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in WASO Based on Actigraphy Data | -1.64 ± 2.286 | -1.17 ± 2.215 |
The ADSD is a PRO measure designed to measure asthma symptoms in adult and adolescent (12 years of age and older) participants diagnosed with mild to severe asthma. ADSD assesses asthma severity based on participant self-report of asthma core symptoms, i.e., difficulty breathing, wheezing, shortness of breath, chest tightness, chest pain, and cough. Participants were asked to complete the ADSD every night before they go to bed, thinking about their asthma symptoms today, from when they got up this morning until now. ADSD is composed of 6 items rated using an 11-point NRS that ranges from 0 = None to 10 = as bad as you can imagine. The total score was calculated by averaging all 6 items and therefore the score ranged from 0 to 10. Higher scores indicated worse outcomes. Baseline value was average of the data from Day -7 to Day -1.
| Score on a scale | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in Asthma Daytime Symptom Diary (ADSD) | -1.78 ± 0.192 | -1.56 ± 0.193 |
The ANSD is a PRO measure designed to measure asthma symptoms in adult and adolescent (12 years of age and older) participants diagnosed with mild to severe asthma. ANSD assesses asthma severity based on participant self-report of asthma core symptoms, i.e., difficulty breathing, wheezing, shortness of breath, chest tightness, chest pain, and cough. Participants were asked to complete the ANSD when getting up, thinking about their asthma symptoms last night from when they went to bed until now. ANSD is composed of 6 items rated using an 11-point NRS that ranges from 0 = None to 10 = as bad as you can imagine. The total score was calculated by averaging all 6 items and therefore the score ranged from 0 to 10. Higher scores indicated worse outcomes. Baseline value was average of the data from Day -6 to Day -1.
| Score on a scale | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in Asthma Nighttime Symptom Diary (ANSD) | -1.58 ± 0.178 | -1.36 ± 0.178 |
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. For pre-BD FEV1, spirometry was performed before IMP administration and after withholding the standard of care asthma treatment which was verified before performing the measurements. Baseline was defined as the last available valid (non-missing) value up to and including the day of first dose of IMP.
| Liter | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in Pre-Bronchodilator Forced Expiratory Volume (Pre-BD FEV1) | 0.49 ± 0.044 | 0.27 ± 0.047 |
AE: any untoward medical occurrence in participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs: AEs that developed or worsened or became serious during TEAE period, defined as time from first administration of IMP (on Day 1) to last administration of IMP + 98 days or until participant switches to commercialized dupilumab or other biologics. SAE: any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. AESI: AE (serious or nonserious) of scientific and medical concern specific to Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor is required.
| Participants | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| Any TEAE | 48 | 46 |
| Any TESAE | 3 | 3 |
| Any TEAESI | 0 | 0 |
Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR) and weight. Criteria for PCSA: SBP: ≤95 millimeters of mercury (mmHg) and decrease from baseline ≥20 mmHg, ≥160 mmHg and increase from baseline ≥20 mmHg; DBP: ≤45 mmHg and decrease from baseline ≥10 mmHg, ≥ 110 mmHg and increase from baseline ≥ 10 mmHg; HR: ≤ 50 beats per minute (bpm) and decrease from baseline ≥ 20 bpm, ≥120 bpm and increase from baseline ≥ 20 bpm; Weight: ≥ 5% increase from baseline, ≥5% decrease from baseline.
| Participants | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| SBP: ≤95 mmHg and decrease from baseline ≥20 mmHg | 0 | 1 |
| SBP: ≥160 mmHg and increase from baseline ≥20 mmHg | 1 | 2 |
| DBP: ≤45 mmHg and decrease from baseline ≥10 mmHg | 0 | 0 |
| DBP: ≥ 110 mmHg and increase from baseline ≥ 10mmHg | 0 | 0 |
| HR: ≤ 50 bpm and decrease from baseline ≥ 20 bpm | 0 | 0 |
| HR: ≥ 120 bpm and increase from baseline ≥ 20 bpm | 0 | 0 |
| Weight: ≥5% increase from baseline | 3 | 6 |
| Weight: ≥5% decrease from baseline | 5 | 4 |
Collected over TEAEs were collected from first dose of study drug (Day 1) up to 12 weeks after last dose of study drug, approximately 30 weeks. All-cause mortality (deaths) were collected from first dose of study drug (Day 1) up to end of study, approximately 39 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dupilumab 200 mg Q2W | 0/100 (0%) | 3/100 (3%) | 13/100 (13%) |
| Placebo | 0/101 (0%) | 3/101 (3%) | 18/101 (17.8%) |
| Event | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| FallInjury, poisoning and procedural complications | 1/100 | 0/101 |
| Tibia FractureInjury, poisoning and procedural complications | 1/100 | 0/101 |
| Depression SuicidalPsychiatric disorders | 1/100 | 0/101 |
| Suicide AttemptPsychiatric disorders | 1/100 | 0/101 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/100 | 0/101 |
| Pancreatitis AcuteGastrointestinal disorders | 0/100 | 1/101 |
| Covid-19 PneumoniaInfections and infestations | 0/100 | 1/101 |
| UrosepsisInfections and infestations | 0/100 | 1/101 |
| NephrolithiasisRenal and urinary disorders | 0/100 | 1/101 |
| Event | Dupilumab 200 mg Q2W | Placebo |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 9/100 | 14/101 |
| NasopharyngitisInfections and infestations | 4/100 | 7/101 |
The Intent-to-treat (ITT) analysis set consisted of all randomized participants.
| Age, Continuous(Years) | Dupilumab 200 mg Q2W | Placebo | Total |
|---|---|---|---|
| Mean | 46.9 ± 12.63 | 46.6 ± 12.71 | 46.7 ± 12.64 |
| Sex: Female, Male(Participants) | Dupilumab 200 mg Q2W | Placebo | Total |
|---|---|---|---|
| Female | 68 | 76 | 144 |
| Male | 33 | 25 | 58 |
| Race (NIH/OMB)(Participants) | Dupilumab 200 mg Q2W | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 3 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 4 | 4 | 8 |
| White | 92 | 92 | 184 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Sleep Disturbance Score(Score on a scale) | Dupilumab 200 mg Q2W | Placebo | Total |
|---|---|---|---|
| Mean | 1.89 ± 0.769 | 1.83 ± 0.754 | 1.86 ± 0.760 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Aug 2020 to primary completion in Oct 2023, 37 months.
Results were first posted in Nov 2024, 1 year 1 month after primary completion.
Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 37 months is above that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab